Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer
To request a program, click HERE.
This 60-minute CME-certified activity can be hosted in conjunction with your institution's regularly-scheduled grand rounds or tumor board meetings, and will include audience polling questions interwoven with didactic presentation.
Given the recent approval of several PARP inhibitors in the maintenance setting and as standalone therapies for managing recurrent ovarian cancer, the on-going development of novel PARP inhibitors, and the volume of data emerging from clinical trials evaluating PARP inhibitors either alone or in combination with other therapies, it is critical for providers to assess the efficacy, safety, and the most up-to-date data from recent clinical trials so they can use these agents optimally to manage their patients.
A limited number of programs are available - request yours today!
This activity is intended for community and academic medical oncologists, gyencologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.
Upon completion of this activity learners should be able to:
- Assess the efficacy and safety of PARP inhibitors of their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
- Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
- Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
- Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, Inc.
Faculty Experts Available to Present at Your Institution
Thomas Herzog, MD (University of Cincinnati Cancer Institute) - Course Director
Michael Birrer, MD, PhD (Harvard Medical School)
Robert Coleman, MD, FACOG, FACS (MD Anderson Cancer Center)
Ursula Matulonis, MD (Dana-Farber/Harvard Cancer Center)
Bradley Monk, MD, FACS, FACOG (The University of Arizona)
R. Wendel Naumann, MD, FACOG, FACS (Levine Cancer Institute)
David O'Malley, MD (The Ohio State University Wexner Medical Center)
Shannon Westin, MD, MPH, FACOG (MD Anderson Cancer Center)